Table 1.
Baseline characteristics
| Patient characteristic | Afatinib | Gefitinib | Erlotinib | p-value |
|---|---|---|---|---|
| No. of patients | 165 | 230 | 72 | |
| Age (yr) | ||||
| Median (range) | 57 (30-79) | 64 (29-87) | 59 (36-77) | < 0.001 |
| < 60 | 93 (56.4) | 79 (34.3) | 38 (52.8) | < 0.001 |
| ≥ 60 | 72 (43.6) | 151(65.7) | 34 (47.2) | |
| Sex | ||||
| Male | 85 (51.5) | 60 (26.1) | 39 (54.2) | < 0.001 |
| Female | 80 (48.5) | 170 (73.9) | 33 (45.8) | |
| ECOG PS | ||||
| 0 | 42 (25.5) | 56 (24.3) | 24 (33.3) | 0.658 |
| 1 | 114 (69.0) | 160 (69.6) | 44 (61.1) | |
| 2 | 9 (5.5) | 14 (6.1) | 4 (5.6) | |
| Smoking status | ||||
| Never smoker | 99 (60.0) | 180 (78.3) | 41 (56.9) | < 0.001 |
| Current or ex-smoker | 66 (40.0) | 50 (21.7) | 31 (43.1) | |
| EGFR mutation type | ||||
| Exon 19 deletion | 114 (69.1) | 122 (53.0) | 40 (55.6) | 0.002 |
| Exon 21 L858R | 37 (22.4) | 96 (41.8) | 27 (37.5) | |
| Uncommon EGFR | 14 (8.5) | 12 (5.2) | 5 (6.9) |
Values are presented as median (range) or number (%). Uncommon EGFR: the tumor contains a mutation other than del19 or L858R. ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, epidermal growth factor receptor.